Literature DB >> 26206483

Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.

Xiaopeng Lan1, Guoliang Lu1, Chuanwei Yuan1, Shaowei Mao1, Wei Jiang2, Yougen Chen1, Xunbo Jin1, Qinghua Xia3.   

Abstract

PURPOSES: The epithelial-mesenchymal transition (EMT) plays an important role in cancer metastasis. Previous studies have reported that valproic acid (VPA) suppresses prostate carcinoma (PCa) cell metastasis and down-regulates SMAD4 protein levels, which is the key molecule in TGF-β-induced EMT. However, the correlation between VPA and the EMT in PCa remains uncertain.
METHODS: Markers of the EMT in PCa cells and xenografts were molecularly assessed after VPA treatment. The expression and mono-ubiquitination of SMAD4 were also analyzed. After transfection with plasmids that express SMAD4 or short hairpin RNA for SMAD4 down-regulation, markers of EMT were examined to confirm whether VPA inhibits the EMT of PCa cells through the suppression of SMAD4.
RESULTS: VPA induced the increase in E-cadherin (p < 0.05), and the decrease in N-cadherin (p < 0.05) and Vimentin (p < 0.05), in PCa cells and xenografts. SMAD4 mRNA and protein levels were repressed by VPA (p < 0.05), whereas the level of mono-ubiquitinated SMAD4 was increased (p < 0.05). SMAD4 knockdown significantly increased E-cadherin expression in PC3 cells, but SMAD4 over-expression abolished the VPA-mediated EMT-inhibitory effect.
CONCLUSIONS: VPA inhibits the EMT in PCa cells via the inhibition of SMAD4 expression and the mono-ubiquitination of SMAD4. VPA could serve as a promising agent in PCa treatment, with new strategies based on its diverse effects on posttranscriptional regulation.

Entities:  

Keywords:  Epithelial–mesenchymal transition; Prostate carcinoma; SMAD4; Valproic acid

Mesh:

Substances:

Year:  2015        PMID: 26206483     DOI: 10.1007/s00432-015-2020-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  43 in total

1.  TIF1γ requires sumoylation to exert its repressive activity on TGFβ signaling.

Authors:  Laurent Fattet; Anne-Sophie Ay; Benjamin Bonneau; Laurent Jallades; Ivan Mikaelian; Isabelle Treilleux; Germain Gillet; Cédric Hesling; Ruth Rimokh
Journal:  J Cell Sci       Date:  2013-06-20       Impact factor: 5.285

Review 2.  Breast cancer stem cells, EMT and therapeutic targets.

Authors:  Srishti Kotiyal; Susinjan Bhattacharya
Journal:  Biochem Biophys Res Commun       Date:  2014-09-26       Impact factor: 3.575

Review 3.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

4.  Neuroprotective effects of valproic acid against hemin toxicity: possible involvement of the down-regulation of heme oxygenase-1 by regulating ubiquitin-proteasomal pathway.

Authors:  Kyoung Ja Kwon; Jung Nam Kim; Min Kyeong Kim; Su Young Kim; Kyu Suk Cho; Se Jin Jeon; Hahn Young Kim; Jong Hoon Ryu; Sun-Young Han; Jae Hoon Cheong; Louis J Ignarro; Seol-Heui Han; Chan Young Shin
Journal:  Neurochem Int       Date:  2013-01-05       Impact factor: 3.921

Review 5.  TGF-β signalling and its role in cancer progression and metastasis.

Authors:  Yvette Drabsch; Peter ten Dijke
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

6.  Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes.

Authors:  Ji-Young Choi; Jong-Ho Kim; Sangmee Ahn Jo
Journal:  Biochem Biophys Res Commun       Date:  2014-06-02       Impact factor: 3.575

Review 7.  New and emerging therapies for bone metastases in genitourinary cancers.

Authors:  Philip J Saylor; Andrew J Armstrong; Karim Fizazi; Stephen Freedland; Fred Saad; Matthew R Smith; Bertrand Tombal; Kenneth Pienta
Journal:  Eur Urol       Date:  2012-11-23       Impact factor: 20.096

Review 8.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

9.  Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness.

Authors:  Wei Jiang; Yi Zheng; Zhongxian Huang; Muwen Wang; Yinan Zhang; Zheng Wang; Xunbo Jin; Qinghua Xia
Journal:  Int Urol Nephrol       Date:  2013-11-22       Impact factor: 2.370

Review 10.  New perspectives of valproic acid in clinical practice.

Authors:  Lenka Činčárová; Zbyněk Zdráhal; Jiří Fajkus
Journal:  Expert Opin Investig Drugs       Date:  2013-10-28       Impact factor: 6.206

View more
  16 in total

1.  Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt.

Authors:  Wanhu Zhu; Qing Liang; Xu Yang; Yan Yu; Xiaoying Shen; Guangchun Sun
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 2.  The EMT spectrum and therapeutic opportunities.

Authors:  Dominic C Voon; Ruby Y Huang; Rebecca A Jackson; Jean P Thiery
Journal:  Mol Oncol       Date:  2017-06-19       Impact factor: 6.603

3.  Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.

Authors:  Cinzia Antognelli; Rodolfo Cecchetti; Francesca Riuzzi; Matthew J Peirce; Vincenzo N Talesa
Journal:  J Cell Mol Med       Date:  2018-03-05       Impact factor: 5.310

4.  Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.

Authors:  Muyun Wei; Shaowei Mao; Guoliang Lu; Liang Li; Xiaopeng Lan; Zhongxian Huang; Yougen Chen; Miaoqing Zhao; Yueran Zhao; Qinghua Xia
Journal:  BMC Cancer       Date:  2018-04-17       Impact factor: 4.430

5.  Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines.

Authors:  Alejandro Urdiciain; Elena Erausquin; María V Zelaya; Idoya Zazpe; José L Lanciego; Bárbara Meléndez; Juan A Rey; Miguel A Idoate; Natalia A Riobo-Del Galdo; Javier S Castresana
Journal:  Biology (Basel)       Date:  2021-05-26

6.  MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.

Authors:  Yang Liu; Yumei Li; Rui Wang; Shukui Qin; Jing Liu; Fang Su; Yan Yang; Fuyou Zhao; Zishu Wang; Qiong Wu
Journal:  J Exp Clin Cancer Res       Date:  2016-01-27

Review 7.  Epigenetic modulators as therapeutic targets in prostate cancer.

Authors:  Inês Graça; Eva Pereira-Silva; Rui Henrique; Graham Packham; Simon J Crabb; Carmen Jerónimo
Journal:  Clin Epigenetics       Date:  2016-09-15       Impact factor: 6.551

8.  A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells.

Authors:  Shuang Sha; Yuanfen Zhai; Chengzhao Lin; Heyong Wang; Qing Chang; Shuang Song; Mingqiang Ren; Gentao Liu
Journal:  Oncotarget       Date:  2017-06-07

9.  Vimentin as a target for the treatment of COVID-19.

Authors:  Zhenlin Li; Denise Paulin; Patrick Lacolley; Dario Coletti; Onnik Agbulut
Journal:  BMJ Open Respir Res       Date:  2020-09

10.  Valproic acid Suppresses Breast Cancer Cell Growth Through Triggering Pyruvate Kinase M2 Isoform Mediated Warburg Effect.

Authors:  Zhen Li; Lina Yang; Shuai Zhang; Jiaqi Song; Huanran Sun; Changliang Shan; Dan Wang; Shuangping Liu
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.